Holen Sie sich die Stockscreener-App
1.32
4.35%
-0.06
Handel nachbörslich:
1.34
0.02
+1.52%
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Fed Meeting: Is Akebia Therapeutics Incs ROIC above industry average2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance
Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D DaySlideshow (NASDAQ:AKBA) 2026-04-04 - Seeking Alpha
Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK
Akebia (AKBA) director granted 214,400 options at $1.41, 3-year vest - stocktitan.net
Akebia (NASDAQ: AKBA) director Philip J. Vickers files initial Form 3 - stocktitan.net
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Issues Inducement Grants With Stock Options for New Employees - geneonline.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia's Research and Development Day May Confirm or Undermine Its Kidney Treatment Strategy - Bitget
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia gives 13 new hires stock options for 679,900 shares - stocktitan.net
AKBA: Vafseo and a robust pipeline drive growth, with major clinical milestones expected by 2027 - TradingView
AKBA: Innovative kidney disease pipeline advances with major clinical and commercial catalysts ahead - tradingview.com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets - MarketBeat
Akebia Therapeutics Appoints Philip Vickers, Ph.D. to Board of Directors – Company Details and Nasdaq Listing (2026) - Minichart
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - Sahm
Akebia Therapeutics appoints biopharmaceutical leader Philip Vickers to its board of directors - marketscreener.com
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors - TradingView
Akebia Therapeutics adds Philip Vickers to board of directors By Investing.com - Investing.com India
Akebia Therapeutics (AKBA) appoints Philip Vickers to Board as Steven Gilman retires - stocktitan.net
Akebia Therapeutics adds Philip Vickers to board of directors - investing.com
AKBA.O PE Ratio & Valuation, Is AKBA.O Overvalued - Intellectia AI
AKBA Should I Buy - Intellectia AI
AKBA.O Technical Analysis & Stock Price Forecast - Intellectia AI
AKBA.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKBA.O Forecast — Price Prediction for 2026. Should I Buy AKBA.O? - Intellectia AI
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
10 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Nordea Investment Management Boosts Stake in Akebia Therapeutics - National Today
Nordea Investment Management AB Takes Position in Akebia Therapeutics, Inc. $AKBA - marketbeat.com
Does Akebia Therapeutics Inc offer margin of safety2026 Top Decliners & Weekly Setup with High ROI Potential - baoquankhu1.vn
Fundamentals Check: What is the earnings history of Akebia Therapeutics IncEarnings Overview Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
US Market Recap: What is the next catalyst for Akebia Therapeutics IncPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Vanguard Disaggregates Holdings; Akebia (AKBA) Beneficial Ownership Reported as 0 - Stock Titan
Aug Retail: Is Akebia Therapeutics Inc stock showing strong momentum2026 Top Gainers & Capital Efficient Trading Techniques - baoquankhu1.vn
Street Watch: Can Akebia Therapeutics Inc benefit from deglobalization2026 Opening Moves & Daily Profit Focused Stock Screening - baoquankhu1.vn
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Downgrade Watch: Should I invest in Akebia Therapeutics Inc before earnings2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
Trend Report: What is the earnings history of Akebia Therapeutics IncRecession Risk & Real-Time Buy Zone Alerts - baoquankhu1.vn
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - stocktitan.net
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times
Akebia Announces Approval of Vafseo® (vadadustat) in Australia a - GuruFocus
Is the Options Market Signaling a Surge in Akebia Therapeutics Shares? - Bitget
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock? - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Akebia Q2 2025 Earnings Preview - MSN
AKBA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):